WHO WE ARE
Neurofix is a biotechnology company, focused in the research and development of innovative therapies for the treatment of pathologies related to the Central Nervous System. Its most advanced product in development is the drug NFX88, to treat neuropathic pain in patients with spinal cord injury, currently in a clinical trial Phase 2A study.
The progress of the clinical trial of NFX88 has allowed the integration of Neurofix in the training program Pre-Market Environment (EpM), of Bolsas y Mercados Españoles (BME), as a previous step to the company’s jump to the capital markets. Along this path and to promote its research project, Neurofix has achieved the support of public bodies such as CDTI, ENISA, ICO, IBERAVAL or ICE (Institute for Business Competitiveness, of the Junta de Castilla y León).
With offices in Salamanca, Madrid and the United States, Neurofix wants to provide hope and help people improve their quality of life, through effective and efficient mechanisms of action, backed by solid, high-quality science with a global reach.
WHAT WE WANT
We want to provide hope and help people improve their quality of life, through effective and efficient mechanisms of action, backed by robust science. We develop first-in-class drugs, with no expected adverse effects, of high quality and with a global reach, in the field of Central Nervous System diseases.
Neurofix is a biotechnology company, focused on the research of innovative lipid-based therapies for the treatment of Central Nervous System pathologies.
We want, through originality and innovation, to occupy an unexplored market niche, which generates sufficient profitability, with the development of first-in-class drugs and products, without adverse effects, and indicated for diseases of the Central Nervous System.
Integrity, transparency, honesty, excellence: collaborative attitude, efficiency and high standards of quality and simplicity. We make things easy; molecules and organization are simple and straightforward.